Dr. Silviu Itescu is a globally recognized pioneer in cellular therapies and regenerative medicine. He founded Mesoblast in 2004, serving on its Board of Directors since inception, he assumed the role of Chief Executive Officer and Managing Director in 2011. Under his leadership, Mesoblast has grown into a global leader in allogeneic cellular medicines for inflammatory diseases, with a market cap of approximately $2.48 billion.

Dr. Itescu’s expertise spans stem cell biology, autoimmune disease, organ transplantation and heart failure. His groundbreaking work has positioned Mesoblast at the forefront of developing innovative treatments for inflammatory ailments, cardiovascular disease and back pain. Prior to founding Mesoblast, Dr. Itescu established an international reputation as a physician-scientist, holding faculty positions at prestigious institutions such as Columbia University, University of Melbourne and Monash University in Australia.

Dr. Itescu’s contributions to the field have earned him numerous accolades, including the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture in 2013 BioSpectrum and the Asia Person of the Year in 2011. His influence extends beyond Mesoblast, having consulted international pharmaceutical companies, advised biotechnology investor groups, and served on boards of several publicly listed life science companies.

With a robust pipeline of cellular therapies targeting multi-billion-dollar market opportunities, Dr. Itescu continues to drive Mesoblast’s mission to revolutionize medicine and improve patient outcomes globally.